Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for wound care. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma (“PRP”) gel for use on a variety of exuding wounds. Deerfield entered into a financing with Cytomedix to provide up to $35 million of growth capital to accelerate the commercialization of the Company’s AutoloGel™ System.